Latest Intellectual Property News

ION Video Ltd has responded to ASX inquiries by confirming its recent discussions with Meta Platforms and Alphabet remain preliminary, with no binding agreements or commercial terms agreed. The company emphasised that the engagements are exploratory and non-binding, explaining why earlier disclosure was not required.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

ION Video has entered substantive early-stage discussions with Meta and Alphabet, exploring potential applications of its patented video virtualization technology. These talks are part of a broader engagement with major global tech players, though no formal deals have yet been struck.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.

Vectus Biosystems has completed the sale of its VB4-P5 renal fibrosis compound to Canadian biotech XORTX, receiving a near 10% equity stake and warrants. This move aligns with Vectus’ strategy to develop drug candidates to a stage attractive to partners while focusing on its lead compound VB0004.

Argent BioPharma has finalized the acquisition of CannPal Animal Therapeutics, securing a Phase 3 veterinary epilepsy asset with near-term commercial prospects and an option to acquire the Neuvis® drug delivery platform, enhancing its neurological portfolio and U.S. market ambitions.

WhiteHawk (ASX: WHK) has acquired Quixxi, gaining the Clarity AI platform to extend its cybersecurity services into the burgeoning global AI governance sector. The deal positions WhiteHawk at the convergence of cybersecurity, data governance, and AI risk management amid rapid market growth and regulatory momentum.

Metallium Limited has marked a pivotal quarter with over 40 Flash Joule Heating campaigns completed and a strategic capital raise boosting cash reserves to A$82 million. The company is gearing up for multi-reactor operation at its Texas campus, underpinned by long-term agreements with Indium Corporation and Glencore.

Ainsworth Game Technology Limited has released its Target’s Statement recommending shareholders accept an unconditional proportional off-market takeover bid by Mr Kjerulf David Hastings Ainsworth at $1.30 per share, representing a premium to recent trading prices.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.